28-amino-acid thymic peptide
Thymosin Alpha-1
Synthetic 28-amino-acid thymic peptide for immune modulation.
- Half-life~2 hours plasma
- Dose range1.6 mg subcutaneous, 2 to 3 times weekly · 4 to 12 week cycle
- Reconstituted stability28 days, 2–8 °C
- VerificationCOA included
Mechanism
How it works.
Modulates T-cell function via TLR9 signalling. Supports T-helper cell maturation and NK cell activity.
Research
What the research shows.
Multiple randomised controlled trials show meaningful effects in chronic hepatitis B and cancer-adjunctive contexts. Healthy-adult use is research-context with reasonable but less-established evidence.
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide derived from the thymus. The compound is sold under the licensed-medicine name Thymalfasin (Zadaxin) in over 30 countries for chronic hepatitis B and immune-compromised cancer-patient cohorts.
Most published research is in clinically compromised cohorts where effects are clinically meaningful. Healthy-adult research-context use is reasonable but operates outside the strongest evidence base.
Contraindications
When not to use.
Active autoimmune disease without clinical oversight. Pregnancy. Severe immunosuppression for non-research indications.
Optimal pairings
Stacks well with.
Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.